Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

The National Comprehensive Cancer Network

McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760 · see citing works

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · see citing works

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · see citing works

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583 · see citing works

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · see citing works

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · see citing works

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · see citing works

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · see citing works

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060 · see citing works

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · see citing works

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 882 · see citing works

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 865 · see citing works

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814 · see citing works

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · see citing works

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Palumbo, A. P., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S. Z., Waage, A., Larocca, A., van der Holt, B., Musto, P., Offidani, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70609-0 · Cited by 290 · see citing works

Frontline therapy of multiple myeloma

Moreau, P., Attal, M., & Facon, T. T. F. (2015) · Blood · doi:10.1182/blood-2014-09-568915 · Cited by 286 · see citing works

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Fayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J., Gimsing, P., Termorshuizen, F., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341669 · Cited by 271 · see citing works

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.66 · Cited by 221 · see citing works

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

Nooka, A. K., Kaufman, J. L., Muppidi, S., Langston, A. A., Heffner, L. T., Gleason, C. L., Casbourne, D., Saxe, D., Boise, L., & Lonial, S. (2013) · Leukemia · doi:10.1038/leu.2013.335 · Cited by 195 · see citing works

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

Hulin, C., Belch, A. R., Shustik, C., Petrucci, M. T., Dührsen, U., Lu, J., Song, K., Rodon, P., Pegourié, B., Garderet, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7295 · Cited by 83 · see citing works

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

Palumbo, A. P., Waage, A., Hulin, C., Beksaç, M., Zweegman, S., Gay, F., Gimsing, P., Leleu, X. P., Wijermans, P., Sucak, G. T., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.067058 · Cited by 74 · see citing works

Front line treatment of elderly multiple myeloma in the era of novel agents

Leleu, X. P. (2008) · Biologics · doi:10.2147/btt.s4275 · Cited by 10 · see citing works

Front line treatment of elderly multiple myeloma in the era of novel agents

Leleu, X. P. (2008) · Biologics · doi:10.2147/btt.2009.2524 · Cited by 6 · see citing works

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,027 · see citing works

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Mateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447 · see citing works

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Dimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430 · see citing works

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Xu, J., Chen, L., Yang, S., Sun, Y., Wu, W., Liu, Y., Xu, J., Zhuang, Y., Zhang, W., Weng, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 391 · see citing works

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370 · see citing works

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

Mikhael, J. R., Ismaila, N., Cheung, M. C., Costello, C. L., Dhodapkar, M. V., Kumar, S. K., Lacy, M. Q., Lipe, B. C., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 334 · see citing works

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Moreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 280 · see citing works

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

Facon, T. T. F., Dimopoulos, M. A., Meuleman, N., Belch, A., Mohty, M., Chen, W., Kım, K., Zamagni, E., Rodríguez‐Otero, P., Renwick, W. E. P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0539-0 · Cited by 240 · see citing works

Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival

Turesson, I., Björkholm, M., Blimark, C. H., Kristinsson, S. Y., Vélez, R., & Landgren, O. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13083 · Cited by 180 · see citing works

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Costa, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T. M., Godby, K. N., Silbermann, R. W., Dhakal, B., Bal, S., Giri, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00236-3 · Cited by 176 · see citing works

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Facon, T. T. F., Lee, J. H., Moreau, P., Niesvizky, R., Dimopoulos, M. A., Hájek, R., Pour, L., Jurczyszyn, A. J., Qiu, L., Klippel, Z. K., et al. (2019) · Blood · doi:10.1182/blood-2018-09-874396 · Cited by 129 · see citing works

Biology and therapy of multiple myeloma

Joshua, D., Bryant, C. E., Dix, C. H. K., Gibson, J., & Ho, P. J. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50129 · Cited by 128 · see citing works

Recurrent aphthous ulceration: a review of potential causes and novel treatments

Saikaly, S. K., Saikaly, T. S., & Saikaly, L. E. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1422079 · Cited by 124 · see citing works

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0273-x · Cited by 116 · see citing works

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

Cook, G., Royle, K., Pawlyn, C., Hockaday, A., Shah, V., Kaiser, M., Brown, S., Gregory, W. M., Child, J. A., Davies, F. E., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30220-5 · Cited by 113 · see citing works

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D’Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0142-9 · Cited by 107 · see citing works

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Facon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood · doi:10.1182/blood.2020008787 · Cited by 104 · see citing works

Repurposing old drugs to fight multidrug resistant cancers

Dinić, J., Efferth, T., García‐Sosa, A. T., Grahovac, J., Padrón, J. M., Pajeva, I. K., Rizzolio, F., Saponara, S., Spengler, G., & Tsakovska, I. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100713 · Cited by 100 · see citing works

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Duan, D., Wang, K., Cheng, W., Feng, D., Liu, Y., He, Q., Xu, X., Wang, C., Zhao, S., Lv, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609421 · Cited by 90 · see citing works

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

Dimopoulos, M. A., Špıčka, I., Quach, H., Oriol, A., Hájek, R., Garg, M. K., Beksaç, M., Bringhen, S., Katodritou, E., Chng, W. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02060 · Cited by 80 · see citing works

Second primary malignancies in multiple myeloma: A review

Poh, C., Keegan, T. H. M., & Rosenberg, A. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100757 · Cited by 75 · see citing works

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Jasielec, J. K., Kubicki, T., Raje, N. S., Vij, R., Reece, D. E., Berdeja, J. G., Derman, B. A., Rosenbaum, C. A., Richardson, P. G. G., Gurbuxani, S. K., et al. (2020) · Blood · doi:10.1182/blood.2020007522 · Cited by 74 · see citing works

Current approaches to management of newly diagnosed multiple myeloma

Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 73 · see citing works

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Dumontet, C., Hulin, C., Dimopoulos, M. A., Belch, A. R., Dispenzieri, A. A., Ludwig, H., Rodon, P., Droogenbroeck, J. V., Qiu, L., Cavo, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0133-x · Cited by 73 · see citing works

How I treat multiple myeloma in geriatric patients

Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 72 · see citing works

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

Moreau, P., Zamagni, E., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68 · see citing works

Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany

Eisfeld, C., Kajüter, H., Möller, L., Wellmann, I., Shumilov, E., & Stang, A. (2023) · BMC Cancer · doi:10.1186/s12885-023-10787-5 · Cited by 61 · see citing works

Ixazomib for the treatment of multiple myeloma

Richardson, P. G. G., Zweegman, S., O’Donnell, E., Laubach, J. P., Raje, N. S., Voorhees, P. M., Ferrari, R. H., Skácel, T., Kumar, S. K., & Lonial, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528229 · Cited by 61 · see citing works

Update on the role of lenalidomide in patients with multiple myeloma

Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 59 · see citing works

Perspectives on the Treatment of Multiple Myeloma

Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 58 · see citing works

Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 57 · see citing works

Current Treatment Strategies for Multiple Myeloma

Branagan, A. R., Lei, M. M., Lou, U. Y., & Raje, N. S. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00244 · Cited by 55 · see citing works

Insights on Multiple Myeloma Treatment Strategies

Mateos, M., Ludwig, H., Bazarbachi, A. A., Beksaç, M., Bladé, J., Boccadoro, M., Cavo, M., Delforge, M., Dimopoulos, M. A., Facon, T. T. F., et al. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000163 · Cited by 50 · see citing works

Approach to the Older Adult With Multiple Myeloma

Mina, R., Bringhen, S., Wildes, T. M., Zweegman, S., & Rosko, A. E. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239067 · Cited by 50 · see citing works

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R. A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0384-1 · Cited by 49 · see citing works

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00103-x · Cited by 48 · see citing works

Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

Saleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 48 · see citing works

Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis

Chakraborty, R., Riaz, I. B., Malik, S. U., Marneni, N., Garcia, A. M., Anwer, F., Khorana, A. A., Rajkumar, S. V., Kumar, S. K., Murad, M. H., et al. (2020) · Cancer · doi:10.1002/cncr.32682 · Cited by 48 · see citing works

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

Argueta, C. E., Kashyap, T., Klebanov, B., Unger, T. J., Guo, C., Harrington, S., Baloglu, E., Lee, M., Senapedis, W. T., Shacham, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25368 · Cited by 45 · see citing works

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Davies, F. E., Pawlyn, C., Usmani, S. Z., Miguel, J. F. S., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0205 · Cited by 43 · see citing works

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

Chari, A., Richardson, P. G. G., Romanus, D., Dimopoulos, M. A., Sonneveld, P., Terpos, E., Hájek, R., Raju, A., Palumbo, A. P., Cain, L. E., et al. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1729734 · Cited by 43 · see citing works

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

Bringhen, S., D’Agostino, M., París, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota‐Scalabrini, D., Rosa, L. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.226407 · Cited by 42 · see citing works

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies

Hernández‐Rivas, J., Ríos, R., Encinas, C., Alonso, R., & Lahuerta, J. J. (2022) · Biomarker Research · doi:10.1186/s40364-021-00344-2 · Cited by 40 · see citing works

Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma

Deshantri, A. K., Fens, M. H. A. M., Ruiter, R. W. J., Metselaar, J. M., Storm, G., van Bloois, L., Varela-Moreira, A., Mandhane, S. N., Mutis, T., Martens, A. C., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.028 · Cited by 39 · see citing works

Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

Alonso, R., Cedena, M., Wong, S. W. K., Shah, N. D., Ríos, R., Moraleda, J. M., López‐Jiménez, J., García, C., Bahri, N., Valeri, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001508 · Cited by 38 · see citing works

A comprehensive approach to therapy of haematological malignancies in older patients

Córdoba, R., Eyre, T. A., Klepin, H. D., Wildes, T. M., & Goede, V. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00241-6 · Cited by 38 · see citing works

Induction Therapy for Newly Diagnosed Multiple Myeloma

Paul, B. A., Lipe, B. C., Ocio, E. M., & Usmani, S. Z. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238527 · Cited by 35 · see citing works

Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies

D’Agostino, M., Bertamini, L., Oliva, S., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers11122015 · Cited by 35 · see citing works

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020

Bobin, A., Liuu, É., Moya, N., Gruchet, C., Sabirou, F., Lévy, A., Gardeney, H., Nsiala, L., Cailly, L., Guidez, S., et al. (2020) · Cancers · doi:10.3390/cancers12102885 · Cited by 35 · see citing works

Treatment horizon in multiple myeloma

Soekojo, C. Y., & Chng, W. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13840 · Cited by 35 · see citing works

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis

Piechotta, V., Jakob, T., Langer, P. H., Monsef, I., Scheid, C., Estcourt, L. J., Ocheni, S., Theurich, S., Kuhr, K., Scheckel, B., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013487 · Cited by 35 · see citing works

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial

Askeland, F. B., Haukås, E., Slørdahl, T. S., Klostergaard, A., Alexandersen, T., Osnes, L., Lysén, A., Abdollahi, P., Nielsen, L. K., Hermansen, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00347-8 · Cited by 34 · see citing works

Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects

Kaweme, N. M., Changwe, G. J., & Zhou, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.612696 · Cited by 34 · see citing works

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Dimopoulos, M. A., Grosicki, S., Wiktor-Jędrzejczak, W., Nahi, H., Gruber, A., Hansson, M., Gupta, N., Byrne, C., Labotka, R., Teng, Z., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.011 · Cited by 33 · see citing works

Lenalidomide use in multiple myeloma (Review)

Zhang, C.-W., Wang, Y., & Ge, X. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2705 · Cited by 32 · see citing works

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe

Cavo, M., Terpos, E., Bargay, J., Einsele, H., Cavet, J., Greil, R., & de Wit, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1437345 · Cited by 32 · see citing works

Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis

Kiss, S., Gede, N., Soós, A., Hegyi, P. J., Nagy, B., Imrei, M., Czibere, B., Farkas, N., Hanák, L., Szakács, Z., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103504 · Cited by 31 · see citing works

Immunomodulatory drugs in the treatment of multiple myeloma

Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 30 · see citing works

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials

Mohyuddin, G. R., Koehn, K., Abdallah, A.-O. A., Goodman, A. M., & Prasad, V. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8084 · Cited by 30 · see citing works

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results

Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 30 · see citing works

The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma

Merz, M., Dechow, T. N., Scheytt, M., Schmidt, C., Hackanson, B., & Knop, S. T. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04023-4 · Cited by 29 · see citing works

Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2021) · Cancers · doi:10.3390/cancers13184666 · Cited by 29 · see citing works

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Encinas, C., Hernández‐Rivas, J., Oriol, A., Rosiñol, L., Blanchard, M. J., Bellón, J. M., García‐Sánz, R., de la Rubia, J., de la Guía, A. L., Ubieto, A. J., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00652-2 · Cited by 29 · see citing works

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

Puig, N., Hernández, M. T., Rosiñol, L., González, E., de Arriba, F., Oriol, A., González‐Calle, V., Escalante, F., de la Rubia, J., Gironella, M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00490-8 · Cited by 28 · see citing works

Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy

Nair, R., Gupta, P., & Shanmugam, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1000106 · Cited by 28 · see citing works

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden

Moore, K. L. F., Turesson, I., Genell, A., Klausen, T. W., Knut‐Bojanowska, D., Redder, L., Sverrisdottir, I. S., Thorsen, J., Vangsted, A. J., & Blimark, C. H. (2022) · Haematologica · doi:10.3324/haematol.2021.280424 · Cited by 28 · see citing works

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents

Avet‐Loiseau, H., & Facon, T. T. F. (2018) · Leukemia · doi:10.1038/s41375-018-0098-9 · Cited by 26 · see citing works

Cytokine-induced killer cells: new insights for therapy of hematologic malignancies

Sevari, F. G., Mehdizadeh, A., Abbasi, K., Hejazian, S. S., & Raeisi, M. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03869-z · Cited by 25 · see citing works

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma

Binder, M., Rajkumar, S. V., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dispenzieri, A. A., Hwa, Y. L., Fonder, A. L., Hobbs, M., Hayman, S. R., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25365 · Cited by 25 · see citing works

Frontline therapy for newly diagnosed patients with multiple myeloma

Jung, S., Jo, J., Song, G., Ahn, S., Yang, D., Ahn, J., Kim, H., & Lee, J. (2020) · Blood Research · doi:10.5045/br.2020.s007 · Cited by 25 · see citing works

Progression with clinical features is associated with worse subsequent survival in multiple myeloma

Chakraborty, R., Liu, H. D., Rybicki, L. A., Tomer, J., Khouri, J., Dean, R. M., Faiman, B. M., Kalaycio, M. E., Samaras, C. J., Majhail, N. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25415 · Cited by 24 · see citing works

Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis

Mian, H. S., Mian, O., Rochwerg, B. N., Foley, R., & Wildes, T. M. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.05.014 · Cited by 24 · see citing works

Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials

Martino, M. V., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P. F., et al. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1634541 · Cited by 24 · see citing works

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use

Maclachlan, K. H., Came, N. A., Diamond, B. T., Roshal, M., Ho, C., Thoren, K. L., Mayerhoefer, M. E., Landgren, O., & Harrison, S. J. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.003 · Cited by 23 · see citing works

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review

McCaughan, G. J. B., Gandolfi, S., Moore, J. J., & Richardson, P. G. G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18295 · Cited by 23 · see citing works

The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)

Bergin, K., Wellard, C. J., Moore, E., McQuilten, Z., Blacklock, H. A., Harrison, S. J., Ho, P. J., King, T., Quach, H., Mollee, P. N., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.01.016 · Cited by 23 · see citing works

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist

Wildes, T. M., & Anderson, K. C. (2018) · Hematology · doi:10.1182/asheducation-2018.1.88 · Cited by 21 · see citing works

Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy

Raje, N. S., Mateos, M., Iida, S., & Reece, D. E. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00804-y · Cited by 20 · see citing works

How I treat elderly patients with plasma cell dyscrasias

Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2018) · Aging · doi:10.18632/aging.101707 · Cited by 20 · see citing works

The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma

Fiala, M. A., Foley, N. C., Zweegman, S., Vij, R., & Wildes, T. M. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.03.005 · Cited by 20 · see citing works

The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia

Sim, S., Kalff, A., Tuch, G., Mollee, P. N., Ho, P. J., Harrison, S. J., Gibbs, S. D., Prince, H. M., Spencer, A. G., Joshua, D., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16049 · Cited by 19 · see citing works

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma

Chacon, A., Leleu, X. P., & Bobin, A. (2023) · Cancers · doi:10.3390/cancers15071929 · Cited by 19 · see citing works

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

Dimopoulos, M. A., Niesvizky, R., Weisel, K. C., Siegel, D. S. D., Hájek, R., Mateos, M., Cavo, M., Huang, M., Zahlten‐Kumeli, A., & Moreau, P. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0300-y · Cited by 19 · see citing works

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

Miguel, J. F. S., Gutierrez, M. A. E., Špıčka, I., Mateos, M., Song, K., Craig, M., Bladé, J., Hájek, R., Chen, C. I., Bacco, A. D., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.185991 · Cited by 19 · see citing works

Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives

Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18 · see citing works

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F. F., Evangelista, A., Spada, S., Benevolo, G., Oddolo, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.220657 · Cited by 18 · see citing works

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

Terebelo, H. R., Abonour, R., Gasparetto, C., TOOMEY, K. E., Durie, B. G. M., Hardin, J. W., Jagannath, S., Wagner, L. I., Narang, M., Flick, E. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16139 · Cited by 18 · see citing works

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide

Schoenbeck, K. L., & Wildes, T. M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s196087 · Cited by 17 · see citing works

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Leleu, X. P., Beksaç, M., Chou, T., Dimopoulos, M. A., Yoon, S., Prince, H. M., Pour, L., Shelekhova, T. V., Chari, A., Khurana, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1832672 · Cited by 17 · see citing works

Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper

Grant, S. J., Mian, H. S., Giri, S., Boutin, M., Dottorini, L., Neuendorff, N. R., Krok‐Schoen, J. L., Nikita, N., Rosko, A. E., Wildes, T. M., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.12.001 · Cited by 17 · see citing works

Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma

Elnair, R. A., & Holstein, S. A. (2021) · Drugs · doi:10.1007/s40265-021-01514-0 · Cited by 17 · see citing works

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma

Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Cancers · doi:10.3390/cancers14246216 · Cited by 17 · see citing works

Treatment of older adult or frail patients with multiple myeloma

Grant, S. J., Freeman, C. L. L., & Rosko, A. E. (2021) · Hematology · doi:10.1182/hematology.2021000231 · Cited by 16 · see citing works

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients

Bonello, F., Boccadoro, M., & Larocca, A. (2020) · Cancers · doi:10.3390/cancers12113106 · Cited by 16 · see citing works

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

D’Agostino, M., Paoli, L. D., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.008 · Cited by 16 · see citing works

Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents

Mizuno, S., Kawamura, K., Hanamura, I., Sunami, K., Mori, T., Nakamura, F., Iida, S., Nakazawa, H., Makita, M., Kako, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0478-4 · Cited by 16 · see citing works

Frontline treatment of elderly non transplant‐eligible multiple myeloma patients using CyBorD with or without thalidomide‐based consolidation: a retrospective multi‐centre analysis of real‐world data

Chan, H. S. H., Chai, K., Shih, S., Lewsey, R., Chen, K. Y., McDiarmid, B., Jackson, S., & Simpson, D. (2019) · British Journal of Haematology · doi:10.1111/bjh.16095 · Cited by 15 · see citing works

Therapy-related myeloid neoplasms after treatment for plasma-cell disorders

Chung, A., & Liedtke, M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.003 · Cited by 15 · see citing works

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

Bashir, Q., Chamoun, K., Milton, D. R., Khan, M., Ahmed, S., Mehta, R. S., Popat, U., Kebriaei, P., Nieto, Y. L., Oran, B., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1633633 · Cited by 15 · see citing works

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

Botta, C., Gigliotta, E., Paiva, B., Anselmo, R., Santoro, M., Rodríguez‐Otero, P., Carlisi, M., Conticello, C., Romano, A., Solimando, A. G., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3041 · Cited by 15 · see citing works

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

Bahlis, N. J., Corso, A., Mügge, L.-O., Shen, Z.-X., Desjardins, P., Stoppa, A.-M., Decaux, O., de Revel, T., Granell, M., Marit, G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.111 · Cited by 20 · see citing works

Final Analysis of Overall Survival from the First Trial

Facon, T. T. F., Dimopoulos, M. A., Dispenzieri, A. A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K. C., Ludwig, H., Bahlis, N. J., et al. (2016) · Blood · doi:10.1182/blood.v128.22.241.241 · Cited by 13 · see citing works

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Bahlis, N. J., Corso, A., Mügge, L., Shen, Z., Desjardins, P., Stoppa, A., Decaux, O., de Revel, T., Granell, M., Marit, G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3458.3458 · Cited by 1 · see citing works

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Belch, A. R., Bahlis, N. J., White, D. J., Cheung, M., Chen, C., Shustik, C., Song, K., Tosikyan, A., Dispenzieri, A. A., Anderson, K. C., et al. (2019) · HemaSphere · doi:10.1097/01.hs9.0000567032.31064.27

Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM)

Facon, T. T. F., Dimopoulos, M. A., Hulin, C., Benboubker, L., Belch, A., Ludwig, H., Pinto, A., Attal, M., Cavo, M., Moreau, P., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.330 · Cited by 5 · see citing works